files/journal/2022-09-03_18-51-40-000000_599.png

Research Journal of Medical Sciences

ISSN: Online 1993-6095
ISSN: Print 1815-9346
About US
Editors
Issues
Pages
Indexed in
174
Views
15
Downloads

Evaluation of in Vitro Activity of Fosfomycin Against Uropathgens of Enterobacteriaceae Isolates in the Era of Multidrug Resistance

Prashant Peshattiwar, Himanshu Joshi, Sachin Mishra, Pragati Khanorkar and Rashmi Bhardwaj
Page: 78-82 | Received 10 May 2022, Published online: 20 Jul 2022

Download Citation
https://doi.org/10.36478/10.59218/makrjms.2022.4.78.82

Full Text Reference XML File PDF File

Abstract

The commonly isolated uropathogen are increasingly showing multidrug resistance against routinely used antimicrobial agents and limited therapeutic options for clinicians. Reevaluation of Fosfomycin for therapeutic management of UTI caused by MDR uropathogen is needed as Fosfomycin is broad spectrum antibiotic and has unique property of no cross resistance since it does not share structural similarity with other antibiotics. The present study was conducted to evaluate in vitro activity of Fosfomycin against Extended spectrum Beta–Lactamases (ESBL) producing isolates of Enterobacteriaceae isolated from urine samples. In this prospective study conducted over a period of 1 month , total 568 urine samples were processed. The Enterobacteriaceae isolates were subjected to Kirby – Bauer disk diffusion test to Fosfomycin along with other routinely used urinary antibiotics. . Isolates showing resistance to Cefotaxime (30 μg,) were then tested with phenotypic confirmatory combined disk test using Ceftazidime (30μg) and Ceftazidime ‐clavulanic acid disc (30/10 μg,) for ESBL production. Out of 568 urine samples, 131 (23.06%) showed significant growth of pathogen. Gram Negative isolates from Enterobacteriaceae were the predominant pathogen (n=95, ) 72.51%.. Amongst Enterobacteriaceae. ESBL production was seen in 53.6% (n= 51). Reduced susceptibility was noted for cefotaxime (24.48%), ceftazidime (28.57%), Norfloxacin (30.61%) and Cotrimoxazole (18.36%) in susceptibility testing for E.coli.. Fosfomycin showed susceptibility against Escherichia coli 89.79% ( n = 44). and Klebsiella pneumoniae Fosfomycin susceptibility was 65% (n=26). Nitrofurantoin showed susceptibility for Escherichia coli 71.22 % and Klebsiella pneumoniae 75 % of isolates. Fosfomycin has shown excellent in vitro susceptibility against uropathogenic Enterobacteriaceae isolates. These in vitro findings suggests that Fosfomycin as better therapeutic option for treating uncomplicated UTI.

How to cite this article:

Prashant Peshattiwar, Himanshu Joshi, Sachin Mishra, Pragati Khanorkar and Rashmi Bhardwaj. Evaluation of in Vitro Activity of Fosfomycin Against Uropathgens of Enterobacteriaceae Isolates in the Era of Multidrug Resistance.
DOI: https://doi.org/10.36478/10.59218/makrjms.2022.4.78.82
URL: https://www.makhillpublications.co/view-article/1815-9346/10.59218/makrjms.2022.4.78.82